A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)

This phase II study tests whether carbon ion radiotherapy (a very precise type of radiation therapy) can safely and effectively treat liver cancer (hepatocellular carcinoma) in patients who still have tumor remaining in the liver after a prior treatment called TARE (a type of internal radiation delivered via a catheter into the liver's blood supply). **You may be eligible if...** - You are 19 or older - You have hepatocellular carcinoma confirmed by imaging or biopsy - You have a residual or recurring tumor in the area previously treated with TARE, at least 6 months after that treatment - Your liver function is adequate (Child-Pugh Class A or B score of 7) - Your general performance status is adequate (ECOG 0–2) - Your blood clotting is normal - You are not pregnant and are using contraception if of childbearing age **You may NOT be eligible if...** - You have previously received external beam radiation to the liver - You have an active unresolved infection - You have had another cancer in the past 5 years - You have had a liver transplant - A radiation oncologist determines carbon ion treatment would be unsafe Talk to your doctor to see if this trial is right for you.